Advertisement

Clinical Oral Investigations

, Volume 23, Issue 2, pp 829–838 | Cite as

Overexpression of nicotinamide N-methyltransferase in HSC-2 OSCC cell line: effect on apoptosis and cell proliferation

  • Riccardo Seta
  • Marco Mascitti
  • Roberto Campagna
  • Davide Sartini
  • Stefania Fumarola
  • Andrea Santarelli
  • Michele Giuliani
  • Monia Cecati
  • Lorenzo Lo Muzio
  • Monica EmanuelliEmail author
Original Article
  • 169 Downloads

Abstract

Objectives

Oral squamous cell carcinoma (OSCC) is the most common malignancy of oral cavity. Despite advances in therapeutic approaches, the 5-year survival rate for oral cancer has not improved in the last three decades. Therefore, new molecular targets for early diagnosis and treatment of OSCC are needed. In the present study, we focused on the enzyme nicotinamide N-methyltransferase (NNMT). We have previously shown that enzyme expression is upregulated in OSCC and NNMT knockdown in PE/CA PJ-15 cells significantly decreased cell growth in vitro and tumorigenicity in vivo.

Material and methods

To further explore the role of the enzyme in oral cancer cell metabolism, HSC-2 cells were transfected with the NNMT expression vector (pcDNA3-NNMT) and the effect of enzyme upregulation on cell proliferation was evaluated by MTT assay. Subsequently, we investigated at molecular level the role of NNMT on apoptosis and cell proliferation, by exploring the expression of β-catenin, survivin, and Ki-67 by real-time PCR. Moreover, we performed immunohistochemistry on 20 OSCC tissue samples to explore the expression level of NNMT and survivin ΔEx3 isoform.

Results

Enzyme upregulation significantly increased cell growth in vitro. Moreover, a positive correlation between NNMT and survivin ΔEx3 isoform expression levels was found both in HSC-2 cells and in OSCC tissue samples.

Conclusion

Taken together, our results indicate a possible involvement of NNMT in the proliferation and tumorigenic capacity of OSCC cells and seem to suggest that the enzyme could represent a potential target for the treatment of oral cancer.

Clinical relevance

The involvement of NNMT in cell growth and anti-apoptotic mechanisms seems to suggest that this enzyme could be a new therapeutic target to improve the survival of OSCC patients.

Keywords

NNMT Survivin Cell growth Tumorigenicity Oral cancer 

Notes

Funding

This study was supported by grants from Marche Polytechnic University.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

For this type of study, formal consent is not required.

References

  1. 1.
    Warnakulasuriya S (2009) Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 45:309–316CrossRefGoogle Scholar
  2. 2.
    Petti S (2009) Lifestyle risk factors for oral cancer. Oral Oncol 45:340–350CrossRefGoogle Scholar
  3. 3.
    Gibson MK, Forastiere AA (2006) Reassessment of the role of induction chemotherapy for head and neck cancer. Lancet Oncol 7:565–574CrossRefGoogle Scholar
  4. 4.
    Aksoy S, Szumlanski CL, Weinshilboum RM (1994) Human liver nicotinamide N-methyltransferase. cDNA cloning, expression, and biochemical characterization. J Biol Chem 269:14835–14840Google Scholar
  5. 5.
    Peng Y, Sartini D, Pozzi V, Wilk D, Emanuelli M, Yee VC (2011) Structural basis of substrate recognition in human nicotinamide N-methyltransferase. Biochem 50:7800–7808CrossRefGoogle Scholar
  6. 6.
    Pozzi V, Sartini D, Morganti S, Giuliante R, Di Ruscio G, Santarelli A, Rocchetti R, Rubini C, Tomasetti M, Giannatempo G, Orlando F, Provinciali M, Lo Muzio L, Emanuelli M (2013) RNA-mediated gene silencing of nicotinamide N-methyltransferase is associated with decreased tumorigenicity in human oral carcinoma cells. PLoS One 8:e71272CrossRefGoogle Scholar
  7. 7.
    Sartini D, Muzzonigro G, Milanese G, Pierella F, Rossi V, Emanuelli M (2006) Identification of nicotinamide N-methyltransferase as a novel tumor marker for renal clear cell carcinoma. J Urol 176:2248–2254CrossRefGoogle Scholar
  8. 8.
    Sartini D, Santarelli A, Rossi V, Goteri G, Rubini C, Ciavarella D, Lo Muzio L, Emanuelli M (2007) Nicotinamide N-methyltransferase upregulation inversely correlates with lymph node metastasis in oral squamous cell carcinoma. Mol Med 13:415–421CrossRefGoogle Scholar
  9. 9.
    Sartini D, Muzzonigro G, Milanese G, Pozzi V, Vici A, Morganti S, Rossi V, Mazzucchelli R, Montironi R, Emanuelli M (2013) Upregulation of tissue and urinary nicotinamide N-methyltransferase in bladder cancer: potential for the development of a urine-based diagnostic test. Cell Biochem Biophys 65:473–483CrossRefGoogle Scholar
  10. 10.
    Sartini D, Morganti S, Guidi E, Rubini C, Zizzi A, Giuliante R, Pozzi V, Emanuelli M (2013) Nicotinamide N-methyltransferase in non-small cell lung cancer: promising results for targeted anti-cancer therapy. Cell Biochem Biophys 67:865–873CrossRefGoogle Scholar
  11. 11.
    Emanuelli M, Santarelli A, Sartini D, Ciavarella D, Rossi V, Pozzi V, Rubini C, Lo Muzio L (2010) Nicotinamide N-Methyltransferase upregulation correlates with tumour differentiation in oral squamous cell carcinoma. Histol Histopathol 25:15–20Google Scholar
  12. 12.
    Sartini D, Pozzi V, Renzi E, Morganti S, Rocchetti R, Rubini C, Santarelli A, Lo Muzio L, Emanuelli M (2012) Analysis of tissue and salivary nicotinamide N-methyltransferase in oral squamous cell carcinoma: basis for the development of a noninvasive diagnostic test for early-stage disease. Biol Chem 393:505–511CrossRefGoogle Scholar
  13. 13.
    Balducci E, Emanuelli M, Raffaelli N, Ruggieri S, Amici A, Magni G, Orsomando G, Polzonetti V, Natalini P (1995) Assay methods for nicotinamide mononucleotide adenylyltransferase of wide applicability. Anal Biochem 228:64–68CrossRefGoogle Scholar
  14. 14.
    Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254CrossRefGoogle Scholar
  15. 15.
    Wu Y, Siadaty MS, Berens ME, Hampton GM, Theodorescu D (2008) Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration. Oncogene 27:6679–6689CrossRefGoogle Scholar
  16. 16.
    Tang SW, Yang TC, Lin WC, Chang WH, Wang CC, Lai MK, Lin JY (2011) Nicotinamide N-methyltransferase induces cellular invasion through activating matrix metalloproteinase-2 expression in clear cell renal cell carcinoma cells. Carcinogenesis 32:138–145CrossRefGoogle Scholar
  17. 17.
    Yu T, Wang YT, Chen P, Li YH, Chen YX, Zeng H, Yu AM, Huang M, Bi HC (2015) Effects of nicotinamide N-methyltransferase on PANC-1 cells proliferation, metastatic potential and survival under metabolic stress. Cell Physiol Biochem 35:710–721CrossRefGoogle Scholar
  18. 18.
    Parsons RB, Aravindan S, Kadampeswaran A, Evans EA, Sandhu KK, Levy ER, Thomas MG, Austen BM, Ramsden DB (2011) The expression of nicotinamide N-methyltransferase increases ATP synthesis and protects SH-SY5Y neuroblastoma cells against the toxicity of complex I inhibitors. Biochem J 436:145–155CrossRefGoogle Scholar
  19. 19.
    Zhang J, Wang Y, Li G, Yu H, Xie X (2014) Down-regulation of nicotinamide N-methyltransferase induces apoptosis in human breast cancer cells via the mitochondria-mediated pathway. PLoS One 9:e89202CrossRefGoogle Scholar
  20. 20.
    Xie X, Yu H, Wang Y, Zhou Y, Li G, Ruan Z, Li F, Wanga X, Liu H, Zhang J (2014) Nicotinamide N-methyltransferase enhances the capacity of tumorigenesis associated with the promotion of cell cycle progression in human colorectal cancer cells. Arch Biochem Biophys 564:52–66CrossRefGoogle Scholar
  21. 21.
    Sartini D, Seta R, Pozzi V, Morganti S, Rubini C, Zizzi A, Tomasetti M, Santarelli L, Emanuelli M (2015) Role of nicotinamide N-methyltransferase in non-small cell lung cancer: in vitro effect of shRNA-mediated gene silencing on tumourigenicity. Biol Chem 396:225–234CrossRefGoogle Scholar
  22. 22.
    Pozzi V, Sartini D, Rocchetti R, Santarelli A, Rubini C, Morganti S, Giuliante R, Calabrese S, Di Ruscio G, Orlando F, Provinciali M, Saccucci F, Lo Muzio L, Emanuelli M (2015) Identification and characterization of cancer stem cells from head and neck squamous cell carcinoma cell lines. Cell Physiol Biochem 36:784–798CrossRefGoogle Scholar
  23. 23.
    De Maria S, Pannone G, Bufo P, Santoro A, Serpico R, Metafora S, Rubini C, Pasquali D, Papagerakis SM, Staibano S, De Rosa G, Farina E, Emanuelli M, Santarelli A, Mariggiò MA, Lo Russo L, Lo Muzio L (2009) Survivin gene-expression and splicing isoforms in oral squamous cell carcinoma. J Cancer Res Clin Oncol 135:107–116CrossRefGoogle Scholar
  24. 24.
    Sah NK, Seniya C (2015) Survivin splice variants and their diagnostic significance. Tumour Biol 36:6623–6631CrossRefGoogle Scholar
  25. 25.
    Lo Muzio L, Staibano S, Pannone G, Mignogna MD, Mariggiò A, Salvatore G, Chieffi P, Tramontano D, De Rosa G, Altieri DC (2001) Expression of the apoptosis inhibitor survivin in aggressive squamous cell carcinoma. Exp Mol Pathol 70:249–254CrossRefGoogle Scholar
  26. 26.
    Ge QX, Li YY, Nie YQ, Zuo WG, Du YL (2013) Expression of survivin and its four splice variants in colorectal cancer and its clinical significances. Med Oncol 30:535CrossRefGoogle Scholar
  27. 27.
    Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I, Reed JC (2003) HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 22:2729–2240CrossRefGoogle Scholar
  28. 28.
    Song Z, Yao X, Wu M (2003) Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of surviving during taxol-induced apoptosis. J Biol Chem 278:23130–23140CrossRefGoogle Scholar
  29. 29.
    Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, Watanabe N (2000) Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 91:1204–1209CrossRefGoogle Scholar
  30. 30.
    Wang L, Zhang GM, Feng ZH (2003) Down-regulation of survivin expression reversed multidrug resistance in adriamycin-resistant HL-60/ADR cell line. Acta Pharmacol Sin 24:1235–1240Google Scholar
  31. 31.
    Martinez A, Bellosillo B, Bosch F, Ferrer A, Marce S, Villamor N, Ott G, Montserrat E, Campo E, Colomer D (2004) Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 164:501–510CrossRefGoogle Scholar
  32. 32.
    Mahotka C, Krieg T, Krieg A, Wenzel M, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD (2002) Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 100:30–36CrossRefGoogle Scholar
  33. 33.
    Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD (1999) Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59:6097–6102Google Scholar
  34. 34.
    Waligórska-Stachura J, Andrusiewicz M, Sawicka-Gutaj N, Biczysko M, Jankowska A, Kubiczak M, Czarnywojtek A, Wrotkowska E, Ruchała M (2014) Survivin delta Ex3 overexpression in thyroid malignancies. PLoS One 9:e100534CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Riccardo Seta
    • 1
  • Marco Mascitti
    • 1
  • Roberto Campagna
    • 1
  • Davide Sartini
    • 1
  • Stefania Fumarola
    • 1
  • Andrea Santarelli
    • 1
  • Michele Giuliani
    • 2
  • Monia Cecati
    • 1
  • Lorenzo Lo Muzio
    • 2
  • Monica Emanuelli
    • 1
    Email author
  1. 1.Department of Clinical SciencesPolytechnic University of MarcheAnconaItaly
  2. 2.Department of Clinical and Experimental MedicineUniversity of FoggiaFoggiaItaly

Personalised recommendations